We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer.
- Authors
June-Koo Lee; Dong-Wan Kim; Bhumsuk Keam; Tae Min Kim; Se-Hoon Lee; Young-Joo Kim; Dae Seog Heo
- Abstract
Purpose To investigate the impact of targeted treatment on direct medical costs of patients with advanced non-small cell lung cancer (NSCLC). Materials and Methods Medical records of 108 stage IIIB/IV NSCLC patients treated in Seoul National University Hospital between 2003 and 2009, were reviewed to collect medical resources utilization data from the diagnosis of stage IIIB/IV NSCLC to the end of active anti-cancer treatment. The direct medical costs were calculated by multiplying the number of medical resources used by the unit price. All costs were expressed in US dollars for each patient. Results The mean total direct medical costs were $34,732 (standard deviation, 21,168) in the study cohort. The mean total direct medical costs were higher in epidermal growth factor receptor (EGFR) mutation (EGFR MT)-positive patients than EGFR wild-type (EGFR WT) patients ($41,403 vs. $30,146, p=0.005). However, the mean monthly direct medical costs did not differ significantly between EGFR MT-positive patients and EGFR WT patients ($2,120 vs. $2,702, p=0.119) because of the longer duration of active anti-cancer treatment in EGFR MT-positive patients. This discrepancy was mainly attributable to EGFR MT-positive patients' lower non-chemotherapy costs ($948 vs. $1,522, p=0.007). The total and monthly direct medical costs of ALK fusion-positive patients who did not receive ALK inhibitors did not differ from WT/WT patients. Conclusion This study suggests that the availability of targeted agents for EGFR MT-positive patients lowers the mean monthly medical costs by prolonging survival and diminishing the use of other medical resources, despite the considerable drug costs.
- Subjects
MEDICAL care costs; CANCER treatment; NON-small-cell lung carcinoma; LUNG cancer patients; STANDARD deviations; SOUL Taehakkyo; EPIDERMAL growth factor receptors; ANAPLASTIC lymphoma kinase; PROTEIN kinase inhibitors
- Publication
Cancer Research & Treatment, 2015, Vol 47, Issue 2, p182
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2013.227